CHEK1 and essential thrombocythemia: Because a significant fraction of LumA BCs after treatment with chemotherapy and ET develop a metastatic ET resistant phenotype [2, 4], we reasoned that the evaluation of the survival probability as a function of CHK1 expression in patients carrying LumA BCs that underwent both chemotherapy and ET administration would provide clues to address this issue [27].